- Conditions: Solid Tumors; Lymphoma
Intervention: Biological: LY2875358
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Not yet recruiting - verified May 2012 - A Study to Compare LY2963016 to Lantus After a Single Dose to Subjects With Type 1 Diabetes MellitusCondition: Diabetes Mellitus, Type 1
Interventions: Drug: LY2963016; Drug: Lantus
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Not yet recruiting - verified May 2012 - Condition: Multiple Myeloma
Interventions: Drug: Placebo; Drug: Dexamethasone; Drug: Bortezomib; Biological: Tabalumab
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Not yet recruiting - verified May 2012 - Condition: Whiplash Injuries
Interventions: Drug: Atomoxetine; Drug: Citalopram
Sponsors: Vrije Universiteit Brussel; Vrije Universiteit Brussel
Not yet recruiting - verified May 2012 - Condition: Psoriasis
Interventions: Drug: 80 mg ixekizumab Dosing Regimen; Drug: 50 mg etanercept; Drug: Placebo
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Not yet recruiting - verified May 2012 - Condition: Healthy Volunteers
Interventions: Drug: LY2140023 Monohydrate (Reference); Drug: LY2140023 Monohydrate (Test - Low); Drug: LY2140023 Monohydrate (Test - Medium); Drug: LY2140023 Monohydrate (Test - High)
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified May 2012 - Condition: Healthy Volunteers
Intervention: Drug: Prasugrel
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Completed - verified May 2012 - Condition: Neoplasms, Hematologic
Interventions: Drug: 200 mg LY2784544; Drug: 400 mg LY2784544; Drug: 600 mg LY2784544
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Not yet recruiting - verified May 2012 - Condition: Diabetes Mellitus, Type 2
Interventions: Drug: 60 mg LY2409021; Drug: Placebo
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified May 2012 - Condition: Type 2 Diabetes Mellitus
Interventions: Drug: Dulaglutide; Drug: Insulin glargine; Drug: Sulfonylureas (SU); Drug: Biguanide
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified April 2012 - Condition: Glioblastoma
Interventions: Drug: LY2157299 monohydrate; Drug: Lomustine; Drug: Placebo
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified May 2012 - Condition: Diabetes Mellitus, Type 2
Interventions: Drug: LY2605541; Drug: Insulin glargine
Sponsors: Eli Lilly and Company; Eli Lilly and Company; Boehringer Ingelheim Pharmaceuticals
Recruiting - verified May 2012 - Condition: Coronary Artery Disease
Interventions: Drug: Prasugrel Loading Dose; Drug: Prasugrel Maintenance Dose; Drug: Ticagrelor Maintenance Dose
Sponsors: Daiichi Sankyo Inc.; Daiichi Sankyo Inc.; Eli Lilly and Company
Recruiting - verified April 2012 - Condition: Healthy Male Volunteers
Intervention: Radiation: Drug
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified April 2012 - Condition: Rheumatoid Arthritis
Intervention: Drug: LY2127399
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Not yet recruiting - verified April 2012 - Condition: Diabetes Mellitus, Type 2
Interventions: Drug: BI10773; Drug: BI10773; Drug: BI10773; Drug: BI10773
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals; Eli Lilly and Company
Recruiting - verified May 2012 - Condition: Healthy Volunteer
Interventions: Drug: LY110140; Drug: Placebo
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Not yet recruiting - verified April 2012 - Condition: Alzheimer's Disease
Interventions: Drug: LY2886721; Drug: Placebo
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified April 2012 - Condition: Multiple Myeloma
Interventions: Biological: LY2127399; Drug: Bortezomib; Drug: Dexamethasone
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Not yet recruiting - verified May 2012 - Condition: Type 2 Diabetes Mellitus
Interventions: Drug: LY2189265; Drug: Placebo; Drug: Liraglutide
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified April 2012 - Condition: Fibromyalgia
Interventions: Drug: Duloxetine 60 mg; Drug: Placebo
Sponsors: Eli Lilly and Company; Eli Lilly and Company; Shionogi
Recruiting - verified April 2012 - Condition: Osteoarthritis
Interventions: Drug: duloxetine; Drug: sugar pill
Sponsors: Northwestern University; Northwestern University; Eli Lilly and Company
Recruiting - verified March 2012 - Condition: Healthy Volunteers
Interventions: Drug: LY3016859 IV; Drug: Placebo IV; Drug: LY3016859 SC; Drug: Placebo SC
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified April 2012 - Condition: Cystic Fibrosis
Intervention:
Sponsors: Foundation for the National Institutes of Health; Foundation for the National Institutes of Health; University of Southern California; University of Minnesota - Clinical and Translational Science Institute; M.D. Anderson Cancer Center; Dana-Farber Cancer Institute; Brigham and Women's Hospital; National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); Amgen; AstraZeneca; Eli Lilly and Company; Johnson & Johnson; Merck; Pfizer; Critical Path Institute; Predictive Safety Testing Consortium
Recruiting - verified March 2012 - Condition: Healthy Volunteers
Interventions: Drug: LY2484595; Drug: Placebo; Drug: Moxifloxacin
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified March 2012 - Condition: Healthy Volunteers
Interventions: Drug: LY3009104; Drug: Placebo; Drug: moxifloxacin
Sponsors: Eli Lilly and Company; Eli Lilly and Company; Incyte Corporation
Recruiting - verified March 2012 - Condition: Healthy Volunteers
Interventions: Drug: LY2886721; Drug: Placebo
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified February 2012 - Condition: Acute Coronary Syndrome
Interventions: Drug: Modification of Prasugrel based on a biological assay; Drug: prasugrel / clopidogrel; Device: Verify Now
Sponsors: Assistance Publique - Hôpitaux de Paris; Assistance Publique - Hôpitaux de Paris; Eli Lilly and Company; Daiichi Sankyo Inc.; Allies in Cardiovascular Trials Initiatives and Organized Networks:ACTION; Accumetrics, Inc.; Stentys
Not yet recruiting - verified February 2012 - Condition: Healthy Volunteers
Interventions: Drug: LY3025876; Drug: Placebo
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Active, not recruiting - verified April 2012 - Condition: Advanced Cancer
Intervention: Drug: LY2495655
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified January 2012 - Condition: Healthy Volunteers
Interventions: Drug: LY2979165; Drug: LY2140023; Other: Placebo; Other: Ketamine
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified May 2012 - Condition: Diabetes Mellitus, Type 2
Intervention: Biological: Dulaglutide
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Active, not recruiting - verified May 2012 - Condition: Healthy Volunteers
Interventions: Drug: Placebo; Drug: LY3000328
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Active, not recruiting - verified April 2012 - Condition: Myelofibrosis
Interventions: Drug: Part A LY2784544; Drug: Part B LY2784544
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Not yet recruiting - verified April 2012 - Condition: Type 2 Diabetes
Interventions: Drug: "GLIPULIN:" [insulin glargine, metformin, exenatide (GLP-1-agonist)]; Drug: Insulin glargine, metformin, prandial insulin
Sponsors: University of Washington; University of Washington; Eli Lilly and Company; Sanofi-Aventis; Amylin Pharmaceuticals, Inc.; DexCom, Inc.; Bayer; Medicomp; University of Texas; Department of Veterans Affairs; Biomedical Research Institute of New Mexico
Not yet recruiting - verified February 2012 - Condition: Diabetes Mellitus, Type 2
Interventions: Drug: metformin; Drug: linagliptin; Drug: linagliptin medium dose; Drug: metformin placebo; Drug: metformin placebo
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals; Eli Lilly and Company
Recruiting - verified May 2012 - Condition: Pancreatic Cancer
Interventions: Drug: LY2495655; Drug: Gemcitabine; Drug: Placebo
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Suspended - verified May 2012 - Condition: Non-small Cell Lung Cancer
Interventions: Drug: PemCarbo; Drug: Pem only
Sponsors: Asan Medical Center; Asan Medical Center; Eli Lilly and Company; Korean Cancer Study Group
Recruiting - verified May 2012 - Condition: Fasting
Intervention: Drug: Olanzapine
Sponsors: Dr. Reddy's Laboratories Limited; Dr. Reddy's Laboratories Limited
Completed - verified January 2012 - Condition: Fed
Intervention: Drug: Olanzapine
Sponsors: Dr. Reddy's Laboratories Limited; Dr. Reddy's Laboratories Limited
Completed - verified January 2012 - Conditions: Psoriasis; Skin Diseases; Skin Diseases, Papulosquamous
Interventions: Drug: Placebo; Drug: LY3009104
Sponsors: Eli Lilly and Company; Eli Lilly and Company; Incyte Corporation
Recruiting - verified April 2012 - Conditions: Systemic Lupus Erythematosus; Connective Tissue Disease; Autoimmune Disease
Interventions: Drug: LY2127399; Drug: Placebo
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Enrolling by invitation - verified January 2012 - Condition: Schizophrenia
Intervention: Drug: Pomaglumetad methionil
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified April 2012 - Condition: Pulmonary Arterial Hypertension
Intervention: Drug: Tadalafil- Tablet
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Not yet recruiting - verified May 2012 - Condition: Diabetes Mellitus, Type 1
Interventions: Drug: Glargine; Drug: LY2605541; Drug: Insulin Lispro
Sponsors: Eli Lilly and Company; Eli Lilly and Company; Boehringer Ingelheim Pharmaceuticals
Recruiting - verified April 2012 - Condition: Sickle Cell Disease
Intervention: Drug: Prasugrel
Sponsors: Eli Lilly and Company; Eli Lilly and Company; Daiichi Sankyo Inc.
Recruiting - verified April 2012 - Condition: Diabetes Mellitus, Type 2
Interventions: Drug: LY3009385; Drug: Placebo
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Completed - verified April 2012 - Condition: Hepatic Insufficiency
Intervention: Drug: LY2140023
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified April 2012 - Condition: Type 2 Diabetes Mellitus
Interventions: Drug: Insulin Lispro; Drug: Insulin Aspart
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified January 2012 - Condition: Psoriasis
Interventions: Drug: 80mg LY2439821 Dosing Regimen; Drug: Placebo
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified April 2012 - Condition: Femur Neck Fracture
Interventions: Drug: Teriparatide; Drug: Placebo
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified April 2012 - Condition: Femur Neck Fracture
Interventions: Drug: Teriparatide; Drug: Placebo
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified April 2012 - Condition: Carcinoma, Non Small Cell Lung
Interventions: Drug: Pemetrexed; Drug: Gefitinib
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified April 2012 - Condition: Diabetes Mellitus, Type 2
Interventions: Drug: LY2605541; Drug: Insulin Glargine; Drug: Insulin Lispro
Sponsors: Eli Lilly and Company; Eli Lilly and Company; Boehringer Ingelheim Pharmaceuticals
Recruiting - verified April 2012 - Condition: Arthritis, Rheumatoid
Interventions: Drug: LY3009104; Drug: Placebo; Drug: LY3009104; Drug: Placebo
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified February 2012 - Condition: Gestational Diabetes Mellitus
Intervention:
Sponsors: Universitaire de Sherbrooke; Universitaire de Sherbrooke; Eli Lilly and Company
Recruiting - verified December 2011 - Condition: Type 2 Diabetes Mellitus
Interventions: Drug: LY2189265; Drug: Sulfonylureas (SU); Drug: Biguanides; Drug: Thiazolidinedione (TZD); Drug: alpha-glucosidase inhibitor (a-GI); Drug: Glinides
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified March 2012 - Conditions: Nonsquamous Nonsmall Cell Neoplasm of Lung; Non-small Cell Lung Cancer Metastatic; Non-small Cell Lung Cancer Stage IIIB
Intervention: Drug: Pemetrexed
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified January 2012 - Condition: Metastatic Cancer
Intervention: Drug: LY3007113
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified April 2012 - Condition: Benign Prostatic Hyperplasia
Interventions: Drug: Tadalafil; Drug: Placebo
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified April 2012 - Condition: Depressive Disorder, Major
Interventions: Drug: LY2216684; Drug: Quinidine
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified April 2012 - Condition: Depressive Disorder, Major
Interventions: Drug: LY2216684; Drug: Clarithromycin
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Completed - verified January 2012 - Condition: Diabetes Mellitus, Type 2
Interventions: Drug: Ortho-Cyclen; Biological: Dulaglutide
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Completed - verified May 2012 - Condition: Diabetes Mellitus, Type 1
Interventions: Drug: Glargine; Drug: LY2605541; Drug: Insulin Lispro
Sponsors: Eli Lilly and Company; Eli Lilly and Company; Boehringer Ingelheim Pharmaceuticals
Recruiting - verified April 2012 - Condition: Alzheimer's Disease
Interventions: Other: PET scan using florbetapir; Other: MRI Scan
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified May 2012 - Condition: Schizophrenia
Interventions: Drug: LY2140023; Drug: Placebo
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified April 2012 - Condition: Type 2 Diabetes
Intervention:
Sponsors: Foundation for the National Institutes of Health; Foundation for the National Institutes of Health; National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); Juvenile Diabetes Research Foundation; Amylin Pharmaceuticals, Inc.; Merck; Pfizer; Eli Lilly and Company; Takeda Global Research & Development Center, Inc.; Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Novartis
Recruiting - verified October 2011 - Condition: Healthy Volunteers
Interventions: Drug: LY2484595 Reference Formulation (RF); Drug: LY2484595 spray-dried solid dispersion-propyl gallate (SDSD-PG)
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Completed - verified January 2012 - Condition: Diabetes Mellitus, Type 2
Interventions: Drug: LY2409021; Drug: Placebo; Drug: Moxifloxacin
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Completed - verified March 2012 - Condition: Diabetes Mellitus
Interventions: Drug: LY2963016; Drug: Lantus
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified January 2012 - Condition: Healthy Subjects
Interventions: Drug: LY2484595; Drug: Placebo; Drug: Ketoconazole
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Completed - verified February 2012 - Condition: Healthy Volunteers
Interventions: Drug: LY3031207; Drug: Placebo; Drug: Celecoxib
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Completed - verified April 2012 - Condition: Pelvis Pain Chronic
Intervention: Drug: Duloxetine
Sponsors: University of Maryland; University of Maryland; Eli Lilly and Company
Recruiting - verified October 2011 - Condition: Recurrent Gliomas
Interventions: Drug: Enzastaurin (LY317615); Drug: Carboplatin
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified March 2012 - Condition: Extensive Stage Small Cell Lung Carcinoma
Interventions: Drug: LY2510924; Drug: Carboplatin; Drug: Etoposide
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified February 2012 - Condition: Lung Cancer
Interventions: Drug: pemetrexed plus cisplatin; Drug: vinorelbine and docetaxel
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center; Eli Lilly and Company
Recruiting - verified January 2012 - Condition: Diabetes Mellitus, Type 2
Interventions: Drug: Digoxin; Biological: Dulaglutide
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Completed - verified April 2012 - Condition: Diabetes Mellitus, Type 2
Interventions: Drug: metformin placebo; Drug: linagliptin placebo; Drug: metformin; Drug: placebo metformin; Drug: metformin; Drug: linagliptin
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals; Eli Lilly and Company
Recruiting - verified May 2012 - Condition: Diabetes Mellitus, Type 2
Interventions: Drug: Glargine; Drug: LY2605541
Sponsors: Eli Lilly and Company; Eli Lilly and Company; Boehringer Ingelheim Pharmaceuticals
Recruiting - verified April 2012 - Conditions: Solid Tumor; Lymphoma, Malignant
Intervention: Drug: Enzastaurin
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified April 2012 - Condition: Diabetes Mellitus, Type 2
Interventions: Biological: dulaglutide; Drug: Warfarin
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Completed - verified April 2012 - Condition: Osteoporosis
Interventions: Drug: Teriparatide; Drug: Aspara-CA 600 mg; Drug: Alfarol 1.0 ug
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Completed - verified December 2011 - Condition: Sickle Cell Disease
Interventions: Drug: Prasugrel (clinical formulation); Drug: Prasugrel (Oral Disintegrating Tablet [ODT])
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Completed - verified October 2011 - Condition: Chronic Kidney Disease
Interventions: Drug: LY2623091; Drug: Eplerenone
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified April 2012 - Condition: Healthy Subjects
Interventions: Drug: LY2140023; Drug: Ammonium chloride; Drug: Sodium bicarbonate
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Completed - verified October 2011 - Condition: Hyperlipidemia
Interventions: Drug: LY3015014 (intravenously); Drug: Placebo (intravenously); Drug: LY3015014 (subcutaneously); Drug: Placebo (subcutaneously)
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified May 2012 - Condition: Diabetes Mellitus, Type 1
Interventions: Drug: LY2963016; Drug: Lantus; Drug: Insulin Lispro
Sponsors: Eli Lilly and Company; Eli Lilly and Company; Boehringer Ingelheim Pharmaceuticals
Recruiting - verified April 2012 - Condition: Diabetes Mellitus, Type 2
Interventions: Drug: LY2963016; Drug: Lantus; Drug: Oral Antihyperglycemic Medications (OAMs)
Sponsors: Eli Lilly and Company; Eli Lilly and Company; Boehringer Ingelheim Pharmaceuticals
Recruiting - verified April 2012 - Conditions: Ejaculatory Dysfunction; Hypogonadism
Interventions: Drug: Testosterone Solution 2%; Drug: Placebo Solution
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified April 2012 - Condition: Diabetes Mellitus, Type 2
Interventions: Drug: BI 10773; Drug: BI 10773; Drug: BI 10773; Drug: linagliptin; Drug: BI 10773 linagliptin FDC; Drug: BI 10773 linagliptin FDC; Drug: high dose BI 10773 placebo; Drug: high dose BI 10773 placebo; Drug: high dose BI 10773 placebo; Drug: low dose BI 10773 placebo; Drug: low dose BI 10773 placebo; Drug: low dose BI 10773 placebo; Drug: linagliptin; Drug: linagliptin; Drug: high dose FDC placebo; Drug: high dose FDC placebo; Drug: high dose FDC placebo; Drug: high dose FDC placebo; Drug: low dose FDC placebo; Drug: low dose FDC placebo; Drug: low dose FDC placebo; Drug: linagliptin placebo; Drug: linagliptin placebo; Drug: linagliptin placebo; Drug: BI 10773; Drug: BI 10773 high dose; Drug: BI 10773 low dose
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals; Eli Lilly and Company
Recruiting - verified May 2012 - Condition: Metastatic Breast Cancer
Interventions: Drug: LY2523355; Drug: Ixabepilone; Drug: pegfilgrastim; Drug: filgrastim
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified April 2012 - Condition: Diabetes Mellitus, Type 2
Interventions: Biological: LY2189265; Drug: Sitagliptin
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Completed - verified April 2012 - Condition: Diabetes Mellitus, Type 2
Interventions: Drug: LY2608204; Drug: Glimepiride
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Withdrawn - verified August 2011 - Condition: Depression
Intervention: Drug: LY2940094
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Completed - verified January 2012 - Condition: Type I Diabetes
Interventions: Biological: Insulin Lispro; Biological: Insulin Lispro
Sponsors: Wockhardt; Wockhardt
Not yet recruiting - verified July 2011 - Condition: Diabetes Mellitus, Type 2
Intervention:
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified May 2012 - Condition: Erectile Dysfunction
Interventions: Drug: LY2452473; Drug: Tadalafil; Drug: LY900010
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Completed - verified September 2011 - Conditions: Chronic Inflammatory Disorder; Arthritis, Rheumatoid
Intervention: Drug: LY3009104
Sponsors: Eli Lilly and Company; Eli Lilly and Company; Incyte Corporation
Completed - verified September 2011 - Conditions: Cardiovascular Disease; Diabetes Mellitus, Type 2
Interventions: Drug: Dulaglutide; Drug: Placebo
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified May 2012 - Condition: Advanced Cancer
Intervention: Drug: LY2835219
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified May 2012 - Condition: Advanced Cancer
Intervention: Drug: LY2228820
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified July 2011 - Condition: Rheumatoid Arthritis
Intervention: Drug: Teriparatide
Sponsors: Brigham and Women's Hospital; Brigham and Women's Hospital; Eli Lilly and Company
Recruiting - verified January 2012 - Condition: Metastatic Clear Cell Renal Cell Carcinoma
Interventions: Drug: LY2510924; Drug: Sunitinib
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified April 2012 - Condition: Depressive Disorder, Major
Interventions: Drug: LY2216684; Drug: Activated Charcoal
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Completed - verified September 2011 - Condition: Depressive Disorder, Major
Intervention: Drug: LY2216684
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Completed - verified September 2011 - Conditions: Solid Tumor; Lymphoma, Malignant
Interventions: Drug: warfarin; Drug: enzastaurin
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified August 2011 - Condition: Major Depression
Intervention: Drug: Duloxetine
Sponsors: Université de Montréal; Université de Montréal; Eli Lilly and Company
Recruiting - verified July 2011 - Condition: Bipolar Disorder
Interventions: Drug: LY2979165; Drug: placebo
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified March 2012 - Condition: Major Depressive Disorder
Interventions: Drug: LY2216684; Drug: LY2216684 Placebo; Drug: Alcohol Placebo containing beverage; Drug: Alcohol containing beverage
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Completed - verified September 2011 - Condition: Dyslipidemias
Interventions: Drug: LY2484595; Drug: Placebo; Drug: Atorvastatin
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Completed - verified March 2012 - Condition: Diabetes Mellitus
Interventions: Drug: LY2963016; Drug: Lantus
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Completed - verified August 2011 - Condition: Depressive Disorder, Major
Interventions: Drug: LY2216684; Drug: Ortho Cyclen; Drug: Placebo
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Completed - verified January 2012 - Conditions: Neoplasms; Neoplasm Metastasis; Pancreatic Cancer
Interventions: Drug: LY2157299; Drug: Gemcitabine; Drug: Placebo
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified April 2012 - Condition: Major Depressive Disorder
Intervention: Drug: LY2216684
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified February 2012 - Condition: Muscular Atrophy
Interventions: Drug: LY2495655; Drug: Placebo
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified April 2012 - Condition: Healthy Subjects
Intervention: Drug: LY2886721
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Completed - verified June 2011 - Condition: Tumors
Interventions: Drug: LY2584702 Reference Formulation; Drug: LY2584702 Test Formulation; Drug: Placebo
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Completed - verified October 2011 - Conditions: Coronary Artery Disease; Left Ventricular Dysfunction; Type 2 Diabetes Mellitus
Intervention: Drug: Exenatide
Sponsors: Charles University, Czech Republic; Charles University, Czech Republic; Eli Lilly and Company
Recruiting - verified June 2011 - Condition: Advanced Cancer
Intervention: Drug: LY2584702
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Terminated - verified January 2012 - 12 Week Efficacy and Safety Study of BI 10773 in Hypertensive Patients With Type 2 Diabetes MellitusConditions: Diabetes Mellitus, Type 2; Hypertension
Interventions: Drug: BI 10773; Drug: BI 10773; Drug: Placebo; Drug: Placebo; Drug: Placebo; Drug: Placebo
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals; Eli Lilly and Company
Active, not recruiting - verified May 2012
 |
Eli Lilly - Database of Clinical Trials by Pharmaceutical Companies |
